The future of medicine is personal. A new facility in Hyderabad from biotech firm PopVax, the RNA Foundry, promises to accelerate this shift, moving from one-size-fits-all drugs to treatments tailored to an individual's unique genetic makeup.
Meet PopVax and Its RNA Foundry
Hyderabad-based
biotechnology firm PopVax has officially launched its RNA Foundry, an advanced facility dedicated to the research, development, and manufacturing of next-generation RNA medicines. Founded in 2021, PopVax is a 'full-stack' company, meaning it handles the entire process from initial design to final production in-house. This new foundry, opened in late October 2026, is the heart of its operations, designed to rapidly move novel treatments from a computer concept to a clinical-grade product in months instead of years. The company, which operates with the ambitious mission to save one million lives annually, is backed by prominent global funders, including the Gates Foundation and Vitalik Buterin's Balvi Fund. While PopVax has several vaccines in its pipeline, including a COVID-19 candidate that entered clinical trials in Australia, the RNA Foundry's primary mission is to pioneer personalised cancer therapies.
What is Personalised Medicine?
For decades, medicine has largely followed a standard model: a single drug or treatment is developed for a specific disease and given to all patients. Personalised medicine, also known as precision medicine, flips that script. It’s an approach that considers an individual's genetic profile, lifestyle, and environment to create treatments tailored specifically for them. This is particularly revolutionary in oncology. Cancer is not a single disease; it is driven by unique genetic mutations that differ from person to person. A personalised cancer vaccine works by identifying the specific mutations in a patient's tumour. An mRNA vaccine is then created to carry instructions that teach the patient's own immune system to recognise these mutated proteins as foreign and launch a targeted attack, leaving healthy cells unharmed. This moves treatment away from blunt instruments like traditional chemotherapy towards a highly specific, individualised strategy.
How the RNA Foundry Works
The term 'foundry' implies a place where things are forged, and that’s precisely the model PopVax is adopting for medicine. The process begins not with chemicals in a lab, but with data. First, a patient's tumour and healthy tissue are genetically sequenced to pinpoint cancer-specific mutations. PopVax then uses its proprietary artificial intelligence (AI) platform to analyse this data and predict which of these mutations will create 'neoantigens'—abnormal proteins that can trigger a powerful immune response. Once the best targets are identified, the corresponding mRNA sequence is manufactured in the foundry's state-of-the-art cleanrooms. This mRNA is then packaged into a lipid nanoparticle (LNP), a tiny fat bubble that protects the delicate genetic code and delivers it into the body's cells. The company states it can complete this entire cycle—from receiving tumour data to a finished, vialed vaccine—in about eight to ten weeks.
A Leap for India's Biotech Ecosystem
The opening of the RNA Foundry is a significant milestone not just for PopVax, but for India's entire biotechnology and pharmaceutical landscape. The country has long been known as the 'pharmacy of the world' for its prowess in manufacturing generic drugs. However, the RNA Foundry represents a major push into original, cutting edge R&D and the creation of novel therapies. By building an endtoend platform that leverages AIdriven design and rapid, GMPcapable manufacturing, PopVax is positioning India as a hub for innovation in the fastgrowing field of RNA therapeutics. This facility challenges the notion that such advanced work can only happen in Western countries, proving that complex, highquality biologics can be designed and produced in India. The company aims to manufacture over 100 distinct personalised cancer vaccines in its first year of operation, offering its services to patients and clinicians globally.
The Road Ahead
Despite the immense promise, the path for personalised medicine is still unfolding. These treatments are experimental and remain in the early stages of clinical development. The cost is also a significant factor, with each personalised vaccine project being a highly resourceintensive undertaking. Furthermore, the regulatory pathways for medicines made for a single individual are still being established globally. However, the technology is advancing at a breathtaking pace. The success of mRNA vaccines during the COVID?19 pandemic opened the floodgates for research into other applications, from flu and RSV to rare genetic diseases and cancer. Facilities like the PopVax RNA Foundry are critical infrastructure, built on the conviction that the scientific potential to create these therapies should not be held back by a lack of manufacturing capability. By creating this capacity now, PopVax is not just building a factory, but laying the groundwork for the future of medicine.
